

# December 2024 Apple Health Preferred Drug List Class: Antidiabetics

# Overview


---

## ▶ Recap:


- ▶ Top 25 classes 2021 to 2023
- ▶ Antidiabetics Subclasses
- ▶ GLP-1 Agonists

## ▶ GLP-1 Agonists and Diagnoses



# Top 25 Classes by Net Paid – PMPM Increase 2021 to 2023



# Antidiabetics – PMPM 2021 to 2023



# GLP-1 Agonists Policy – Effective 2/1/2022




# GLP-1 Agonists and Chronic Conditions


## ▶ Methodology:

- ▶ Pharmacy and medical claims
- ▶ Pharmacy claims service date range: 1/1/2020 to 6/30/2024
- ▶ For medical claims ICD-10s: 1/1/2018 to 6/30/2024

# Population



# Population






# Population: GLP1 Utilization - Plan

Annual Clients by Plan Using a GLP-1							
CALENDER_YEAR	Community Health Plan of Washington	Coordinated Care of Washington	FFS	Molina Healthcare of Washington Inc	United Health Care Community Plan	Wellpoint Washington Inc	Total
2020	822	613	260	2940	1091	949	<b>6675</b>
2021	1519	1068	372	5018	1786	1532	<b>11295</b>
2022	2245	1592	501	7075	2255	2020	<b>15688</b>
2023	3570	2437	721	10781	3764	2933	<b>24206</b>
2024	3148	2086	479	9582	3456	2389	<b>21140</b>

# Population – GLP1 Use: Drug

GLP1 Utilization by Drug Name Over Time



# GLP1 Policy Analysis

---


## ▶ Inclusion Criteria:

- ▶ Type 2 diabetes with established cardiovascular disease or multiple risk factors
- ▶ Type 2 diabetes that meet trial and failure criteria







## ▶ Assumptions:

- ▶ Patient has appropriately met all trial and failure criteria
- ▶ Patient has appropriately met A1C requirement
- ▶ ICD10s are accurate and appropriate



# GLP1 Policy – Trial and Failure or Established CVD/Multiple Risk Factors




# GLP1 Policy – Trial and Failure or Established CVD/Multiple Risk Factors: Plan



# GLP1 Policy – Trial and Failure or Established CVD/Multiple Risk Factors: Preferred Drugs



# GLP1 Policy – Trial and Failure or Established CVD/Multiple Risk Factors: Non-Preferred Drugs



# Wegovy Analysis

---

## ▶ Inclusion Criteria:


- ▶ Diagnosis of obesity or overweight
- ▶ Established cardiovascular disease
- ▶ No diagnosis of diabetes

## ▶ Assumptions:






- ▶ Patient does not have A1C > 6.5%
- ▶ Patient is receiving appropriate therapy (e.g. antiplatelet, antihypertensive, lipid lower therapy)
- ▶ ICD10s are accurate and appropriate



# Wegovy – Policy Criteria Met



# Wegovy – Policy Criteria Met: Plan



# Wegovy – Policy Criteria Met: Age Group



# GLP1 Utilization – Predicting Use for Weight Loss

---


## ▶ Inclusion Criteria:

- ▶ No diagnosis of diabetes
- ▶ Has a diagnosis for obesity which includes, but is not limited to:
  - Overweight
  - Adults: Body Mass Index 27.0 or greater
  - Pediatrics: Body Mass Index 85<sup>th</sup> percentile or greater
  - Obesity







## ▶ Assumptions:

- ▶ GLP1s that meet inclusion criteria are being prescribed for weight loss
- ▶ ICD10s are accurate and appropriate


# GLP1 Utilization – Predicting Use for Weight Loss




# GLP1 Utilization – Predicting Use for Weight Loss: Plan



# GLP1 Utilization – Predicting Use for Weight Loss: Age Group



# GLP1 Utilization – Predicting Use for Weight Loss: Drug





# GLP1 Utilization – Predicting Use for Sleep Apnea

---


## ▶ Inclusion Criteria:

- ▶ Diagnosis of both obesity and sleep apnea
- ▶ No diagnosis of diabetes







## ▶ Assumptions:

- ▶ Patients who meet inclusion criteria are being prescribed a GLP1 for sleep apnea
- ▶ ICD10s are accurate and appropriate


# GLP1 Utilization – Predicting Use for Sleep Apnea



# GLP1 Utilization – Predicting Use for Sleep Apnea: Plan



# GLP1 Utilization – Predicting Use for Sleep Apnea: Drug



# Discussion

---

- ▶ Expect continued growth in utilization
- ▶ Pipeline
- ▶ Questions?